Physician profile
Matthew E Meyer
NPI 1558328831
$2,428.48
in general payments reported to CMS, 2019-2025
19 companies · $203 in 2025
The $203 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $817 · 2020: $179 · 2022: $562 · 2023: $600 · 2024: $66.25 · 2025: $203.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $870.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $870.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $485.72 | 2019-2023 | Hoffmann |
| Merck Sharp & Dohme LLC | $345.73 | 2019-2025 | Pifeltro, Delstrigo, Zerbaxa |
| Viiv Healthcare Company | $332.20 | 2019-2024 | Cabenuva, Dovato, Rukobia |
| Gilead Sciences, INC. | $229.38 | 2019-2023 | |
| Abbvie INC. | $150.56 | 2022-2024 | |
| Napo Pharmaceuticals INC | $140.64 | 2019-2023 | Mytesi |
| Neurocrine Biosciences, INC. | $138.69 | 2022-2025 | |
| Shionogi INC | $99.96 | 2022-2023 | Fetroja |
| Allergan, INC. | $85.83 | 2019-2020 | |
| Janssen Biotech, INC. | $74.75 | 2019-2023 | Symtuza |
| Insmed, INC. | $70.09 | 2019-2025 | Arikayce |
| Astellas Pharma US INC | $57.38 | 2019 | |
| La Jolla Pharmaceutical Company | $54.28 | 2022-2023 | Xerava |
| Mayne Pharma Commercial LLC | $51.95 | 2019-2020 | |
| Paratek Pharmaceuticals, INC. | $34.09 | 2020-2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vyera Pharmaceuticals, LLC | $22.99 | 2019 | |
| Livanova USA, INC. | $20.78 | 2025 | Vns Therapy Sentiva Model 1000 Generator |
| Vifor Pharma, INC. | $18.55 | 2019 | |
| Genentech USA, INC. | $14.91 | 2025 | Ocrevus Zunovo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Meyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.